SML1315

雷尼司他

≥97% (HPLC)

• 同義詞: (3R)-2′-[(4-Bromo-2-fluorophenyl)methyl]-spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone., AS-3201
• 經驗公式（希爾表示法）: C₁₇H₁₁BrFN₃O₄
• CAS號碼: 147254-64-6
• 分子量：: 420.19
• MDL號碼: MFCD00920915
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329825780
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥97% (HPLC)
• 形狀: powder
• 光學活性: [α]/D -5 to -10°, c = 1.0 in methanol
• 顏色: white to beige
• 溶解度: DMSO: 20 mg/mL, clear
• 儲存溫度: −20°C
• SMILES 字串: O=C(N1CC2=C(F)C=C(Br)C=C2)C3=CC=CN3[C@@]4(CC(NC4=O)=O)C1=O
• InChI: 1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1
• InChI 密鑰: QCVNMNYRNIMDKV-QGZVFWFLSA-N

描述

生化／生理作用

Ranirestat (AS-3201) is an aldose reductase (AR) inhibitor. Aldose reductase is a rate-limiting enzyme in the conversion of D-glucose to fructose via D-sorbitol. Ranirestat has been implicated in diabetic complications (cataract formation, retinopathy, neuropathy, nephropathy). Ranirestat prevents sorbitol accumulation and is thus hoped to be effective in the remedy of diabetic neuropathy.

安全資訊

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H315,H319,H335
• 防範說明: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• 危險分類: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• 標靶器官: Respiratory system
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable